SCHEMBL24468397

SCHEMBL24468397

FC(F)(F)CNCc1ccc(C(F)(F)F)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.48
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
PDE2A O00408 1/20 0.41
KMT2A Q03164 2/20 0.41
DAO P14920 1/20 0.40
CNR1 P21554 2/20 0.39
CNR2 P34972 1/20 0.39
TRPV3 Q8NET8 1/20 0.37
HPGD P15428 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.35
MBOAT4 Q96T53 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30841845 1.00 KDM1A (0.48) KDM1AMAOAMAOBRAB9ANPC1
SCHEMBL24468262 0.87 KDM1A (0.46) KDM1AMAOAMAOBRAB9ANPC1
SCHEMBL10288360 0.83 KDM1A (0.48) KDM1AMAOAMAOBRAB9ANPC1
SCHEMBL30471983 0.83 KDM1A (0.48) KDM1AMAOAMAOBRAB9ANPC1
SCHEMBL23774884 0.81 KDM1A (0.47) KDM1AMAOAMAOBRAB9ANPC1
SCHEMBL24258303 0.80 KDM1A (0.46) KDM1AMAOAMAOBRAB9ANPC1
SCHEMBL30481847 0.80 KDM1A (0.46) KDM1AMAOAMAOBRAB9ANPC1
SCHEMBL10864316 0.80 KDM1A (0.46) KDM1AMAOAMAOBRAB9ANPC1
SCHEMBL25376336 0.79 KDM1A (0.54) KDM1AMAOAMAOBRAB9ANPC1
SCHEMBL25202601 0.79 NPC1 (0.54) KDM1AMAOAMAOBRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4251624-B1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC (US) 2025-10-29 EP disclosed
EP-4567038-A1 NOVEL PRMT5 INHIBITOR AND USE THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2025-06-11 EP disclosed
EP-4567036-A1 NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
US-20240101570-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC. 2024-03-28 US disclosed
US-20230159510-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2023-05-25 US disclosed
US-20230159510-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2023-05-25 US disclosed
WO-2022115377-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC. (US) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101570-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 KDM1A 37/4885MAOA 3279/4885MAOB 3113/4885
US-20230159510-A1 NOVEL PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 KDM1A 41/4885MAOA 4214/4885MAOB 3996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.